• KR-12: Applied Workflows for Antimicrobial Research

  2026-09-11

  KR-12 converts a minimal LL-37 fragment into a practical tool for membrane, biofilm, LPS, and host-response assays. This workflow-focused guide explains how to prepare the TFA salt, select informative endpoints, compare planktonic and biofilm activity, and troubleshoot concentration, matrix, and cytotoxicity effects.

• ATP Strategy for PXDN-Driven Glioblastoma Research

  2026-09-10

  A mechanistic and translational framework for using ATP abundance to strengthen PXDN–LDHA studies in glioblastoma, with practical guidance for cellular ATP quantification, tissue workflows, and causal metabolic validation.

• D-N-Acetylgalactosamine: Workflow and QC Guide

  2026-09-10

  D-N-Acetylgalactosamine (SKU B7904) provides a high-purity, water- and DMSO-soluble reagent for controlled analysis of glycoprotein constituents and glycosylation-related workflows. It is not appropriate for ethanol-based preparation or long-term storage of working solutions, and the guidance below is dossier-based because no directly matched paper evidence was supplied.

• 2X Taq PCR Master Mix for Plant Virus Workflows

  2026-09-09

  Build a practical plant-virus confirmation workflow around direct gel loading, A-tailed amplicons, and disciplined controls. The approach complements image-based sweetpotato virus screening by adding a targeted molecular confirmation step without overstating what either method can prove.

• Ampicillin sodium: Assays, Workflows & Troubleshooting

  2026-09-09

  Build reproducible antibacterial activity assays around Ampicillin sodium, from stock preparation and broth microdilution to resistance-focused interpretation. The workflow also shows how to use reference MIC values, orthogonal readouts, and comparative β-lactam designs without mistaking an in vitro benchmark for a clinical conclusion.

• Anlotinib Hydrochloride: From Assay to Translation

  2026-09-08

  Anlotinib hydrochloride links nanomolar receptor inhibition to measurable endothelial phenotypes and a clinically informative case report. This article presents a translational framework for selecting assays, interpreting pharmacology, and recognizing the limits of preclinical-to-clinical inference.

• Anlotinib: VEGFR2 Inhibition and Tumor Angiogenesis

  2026-09-07

  The reference study established anlotinib as a highly potent, comparatively selective VEGFR2 tyrosine kinase inhibitor whose strongest preclinical effects were directed toward tumor-associated endothelial biology. Its progression from biochemical kinase testing through cellular, ex vivo, and xenograft models provides a useful framework for interpreting anti-angiogenic activity while distinguishing vascular effects from direct tumor-cell cytotoxicity.

• ARL4C, Synoviocyte Proliferation, and RA Progression

  2026-09-07

  This study integrates single-cell and bulk transcriptomic data with cellular perturbation, co-culture, and collagen-induced arthritis experiments to position ARL4C as a regulator of aggressive fibroblast-like synoviocytes and macrophage polarization in rheumatoid arthritis. Its findings connect ARL4C-dependent S-phase progression with PI3K/AKT and MAPK signaling, while suggesting an experimental framework for validating synoviocyte proliferation as a disease-relevant phenotype.

• Tivozanib (AV-951) Assay Workflows

  2026-09-05

  Build more informative VEGFR experiments with Tivozanib (AV-951), from endothelial signaling assays to renal cancer models and combination screens. The workflow separates growth arrest from true cell killing, helping researchers avoid overinterpreting a single viability endpoint.

• Fructus Rubi Glycosides in Androgen-Driven BPH

  2026-09-05

  This study shows that a standardized diterpene glycoside extract from Fructus Rubi reduces androgen-associated prostatic enlargement in cell and rat models. Its innovation is the integration of androgen receptor signaling with the S100A2-mediated TGF-β/Smad axis, providing a mechanistic framework for evaluating a multitarget botanical intervention in benign prostatic hyperplasia.

• Celastrol, Mitochondrial Cholesterol, and Mitophagy

  2026-09-04

  A 2026 Phytomedicine study identifies a CAV-1/SCP2-dependent route by which celastrol redistributes cholesterol into mitochondria, elevates mitochondrial stress, and activates mitophagy in liver cancer. The work connects organelle-specific cholesterol metabolism with tumor suppression and provides a mechanistically focused framework for metabolic and mitophagy studies in liver cancer models.

• EdU Flow Cytometry Assay Kits (Cy5): S-Phase

  2026-09-04

  EdU Flow Cytometry Assay Kits (Cy5) provide denaturation-free detection of DNA synthesis during S phase through copper-catalyzed azide-alkyne cycloaddition (CuAAC). The K1078 workflow supports single-cell proliferation measurements and can be integrated with cell-cycle dyes, antibody panels, genotoxicity studies, and pharmacodynamic experiments.

• Anlotinib Hydrochloride: From Target to Translation

  2026-09-03

  A translational analysis of anlotinib hydrochloride, connecting VEGFR2, PDGFRβ, FGFR1, and ERK biology with functional angiogenesis assays, pharmacokinetic interpretation, competitive positioning, and research-strategy decisions.

• Allosteric PDK4 Inhibitors: Study Insights

  2026-09-02

  The 2019 Journal of Medicinal Chemistry study identified compound 8c as a new anthraquinone-derived allosteric PDK4 inhibitor with nanomolar biochemical activity and activity in metabolic, allergic, and cancer-related models. Its integrated structure–activity, pharmacokinetic, docking, cellular, and animal experiments provide a useful framework for evaluating PDK4-directed metabolic modulation while also showing the translational distance between early lead discovery and clinical treatment.

• Cisapride (R 51619) in Cardiac Safety Screens

  2026-09-02

  Cisapride (R 51619) offers a practical bridge between 5-HT4 receptor biology, hERG channel inhibition, and phenotypic cardiotoxicity assays. This guide shows how to deploy it in iPSC-cardiomyocyte workflows, high-content imaging, and orthogonal electrophysiology while minimizing solvent, exposure, and interpretation errors.

8438 records 1/563 page Next 12345 下5页 Last page